CFDE Data Portal | Search ZNF692-DT

	Label	Description
	ZNF692-DT Gene (Entity type)	ENSG00000227237 - ZNF692 divergent transcript
	GSE193351 ruxolitinib 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 5 V 4 PIRFENIDONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 3 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 verteporfin 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE103510 STAT5 inhibition 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE133447 GSE133448 MED25 ETV4 knockdown UFERSA-PC3 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE99875 everolimus 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE149632 dopamine 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE249544 GSE249637 temozolomide 9 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS

ZNF692-DT

ENSG00000227237 - ZNF692 divergent transcript

GSE193351 ruxolitinib 1 v 2 human dn

A Gene Set from LINCS

GSE226249 5 V 4 PIRFENIDONE HUMAN DN

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 3 v 11 human dn

A Gene Set from LINCS

GSE151090 verteporfin 2 v 4 human up

A Gene Set from LINCS

GSE103510 STAT5 inhibition 2 v 0 human dn

A Gene Set from LINCS

GSE133447 GSE133448 MED25 ETV4 knockdown UFERSA-PC3 2 v 0 human up

A Gene Set from LINCS

GSE99875 everolimus 2 v 0 human dn

A Gene Set from LINCS

GSE149632 dopamine 0 v 6 human up

A Gene Set from LINCS

GSE249544 GSE249637 temozolomide 9 v 5 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.